Since CD73/adenosine signaling dampens these adaptive responses, an anti-CD73 therapy would also in this immune compartment reduce counteracting anti-inflammatory signaling, promote Th1 and Th17 responses and thus have the potential to foster pneumonitis development. This evidence concerns the gene NT5E and pneumonitis.